Chemotherapy: Satraplatin delays progression in prostate cancer

Prostate cancer is the second most common cancer in men worldwide. The FDA approved docetaxel in 2004 as first-line treatment for men with castrate-refractory prostate cancer (CRPC) and this is now the standard treatment for such patients. Patients with metastatic disease, however, eventually discontinue docetaxel

More on Wikipedia

    More on Sciencestage.com

      More on Answers.com

      More on Pubmed

        More on answers.yahoo.com

        News